SEARCH:   Advanced

Blood, 15 November 2008, Vol. 112, No. 10, pp. 4318-4327. Prepublished online as a Blood First Edition Paper on August 21, 2008; DOI 10.1182/blood-2007-06-098020. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2007-06-098020v1 112/10/4318    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kurtzberg, J. Articles by Kernan, N. A. Search for Related Content PubMed PubMed Citation Articles by Kurtzberg, J. Articles by Kernan, N. A. Related Collections Transplantation Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies Joanne Kurtzberg1, Vinod K. Prasad1, Shelly L. Carter2, John E. Wagner3, Lee Ann Baxter-Lowe4, Donna Wall5, Neena Kapoor6, Eva C. Guinan7, Stephen A. Feig8, Elizabeth L. Wagner9, Nancy A. Kernan10, on behalf of the COBLT Steering Committee 1 Duke University Medical Center, Durham, NC; 2 EMMES Corporation, Rockville, MD; 3 University of Minnesota, Minneapolis; 4 University of California, San Francisco; 5 Texas Transplant Institute, San Antonio; 6 Children's Hospital of Los Angeles, CA; 7 Dana-Farber Cancer Institute, Boston, MA; 8 Mattel Children's Hospital, Los Angeles, CA; 9 National Heart, Lung, and Blood Institute, Bethesda, MD; and 10 Memorial Sloan-Kettering Cancer Center, New York, NY Outcomes of unrelated donor cord blood transplantation in 191 hematologic malignancy children (median age, 7.7 years; median weight, 25.9 kg) enrolled between 1999 and 2003 were studied (median follow-up, 27.4 months) in a prospective phase 2 multicenter trial. Human leukocyte antigen (HLA) matching at enrollment was 6/6 (n = 17), 5/6 (n = 58), 4/6 (n = 111), or 3/6 (n = 5) by low-resolution HLA-A, -B, and high-resolution (HR) DRB1. Retrospectively, 179 pairs were HLA typed by HR. The median precryopreservation total nucleated cell (TNC) dose was 5.1 x 107 TNC/kg (range, 1.5-23.7) with 3.9 x 107 TNC/kg (range, 0.8-22.8) infused. The median time to engraftment (absolute neutrophil count > 500/mm3 and platelets 50 000/µL) was 27 and 174 days. The cumulative incidence of neutrophil engraftment by day 42 was 79.9% (95% confidence interval [CI], 75.1%-85.2%); acute grades III/IV GVHD by day 100 was 19.5% (95% CI, 13.9%-25.5%); and chronic GVHD at 2 years was 20.8% (95% CI, 14.8%-27.7%). HR matching decreased the probability of severe acute GVHD. The cumulative incidence of relapse at 2 years was 19.9% (95% CI, 14.8%-25.7%). The probabilities of 6-month and 2-year survivals were 67.4% and 49.5%. Unrelated donor cord blood transplantation from partially HLA-mismatched units can cure many children with leukemias. The study was registered at www.clinicaltrials.gov as #NCT00000603 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Querol, G. J. Mufti, S. G.E. Marsh, A. Pagliuca, A.-M. Little, B. E. Shaw, R. Jeffery, J. Garcia, J. M. Goldman, and J. A. Madrigal Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? Haematologica, April 1, 2009; 94(4): 536 - 541. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020